Detailed resume of RNA m6A demethylases.
- Author:
Dandan SHEN
1
,
2
;
Bo WANG
1
,
2
;
Ya GAO
1
,
2
;
Lijuan ZHAO
1
,
2
;
Yaping BI
1
,
2
;
Jinge ZHANG
1
,
2
;
Ning WANG
3
;
Huiqin KANG
1
,
2
;
Jingru PANG
1
,
2
;
Ying LIU
1
,
2
;
Luping PANG
1
,
2
;
Zhe-Sheng CHEN
4
;
Yi-Chao ZHENG
1
,
2
;
Hong-Min LIU
1
,
2
Author Information
- Publication Type:Review
- Keywords: ALKBH5; Diseases; FTO; Inhibitors; RNA demethylation; Screening
- From: Acta Pharmaceutica Sinica B 2022;12(5):2193-2205
- CountryChina
- Language:English
- Abstract: N6-Methyladenosine (m6A) is the most abundant internal modification in eukaryotic mRNA, playing critical role in various bioprocesses. Like other epigenetic modifications, m6A modification can be catalyzed by the methyltransferase complex and erased dynamically to maintain cells homeostasis. Up to now, only two m6A demethylases have been reported, fat mass and obesity-associated protein (FTO) and alkylation protein AlkB homolog 5 (ALKBH5), involving in a wide range of mRNA biological progress, including mRNA shearing, export, metabolism and stability. Furthermore, they participate in many significantly biological signaling pathway, and contribute to the progress and development of cancer along with other diseases. In this review, we focus on the studies about structure, inhibitors development and biological function of FTO and ALKBH5.
